BridgeBio Oncology Therapeutics Management
Management criteria checks 1/4
BridgeBio Oncology Therapeutics' CEO is Pedro Beltran, appointed in Apr 2026, has a tenure of less than a year. total yearly compensation is $3.11M, comprised of 16.6% salary and 83.4% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth $21.58K. The average tenure of the management team and the board of directors is 0.6 years and 1 years respectively.
Key information
Pedro Beltran
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 16.63% |
| CEO tenure | less than a year |
| CEO ownership | 0.004% |
| Management average tenure | less than a year |
| Board average tenure | 1yr |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$154m |
| Dec 31 2025 | n/a | n/a | -US$134m |
| Sep 30 2025 | n/a | n/a | -US$115m |
| Jun 30 2025 | n/a | n/a | -US$87m |
| Mar 31 2025 | n/a | n/a | -US$81m |
| Dec 31 2024 | US$3m | US$517k | -US$74m |
Compensation vs Market: Pedro's total compensation ($USD3.11M) is about average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Insufficient data to compare Pedro's compensation with company performance.
CEO
Pedro Beltran (55 yo)
Dr. Pedro J. Beltran, M.D., Ph D., is Chief Executive Officer of BridgeBio Oncology Therapeutics, Inc. from April 20, 2026. and as a member of our board of directors since April 2026.He is Chief Scientifi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.8yrs | US$20.00k | no data | |
| Co-Founder | no data | US$700.35k | 0% $ 0 | |
| Chief Medical & Development Officer | 1.8yrs | US$3.23m | 0.0036% $ 21.6k | |
| Chief Executive Officer and Director | less than a year | US$3.11m | 0.0036% $ 21.6k | |
| VP of Finance & Controller | 1.1yrs | no data | 0.00025% $ 1.5k | |
| Chief Operating Officer | less than a year | no data | 0.00076% $ 4.5k | |
| Vice President of Legal | no data | no data | no data | |
| Senior Vice President of Drug Discovery | no data | no data | no data | |
| Senior Vice President of Chemistry | 1.8yrs | no data | no data | |
| Senior Vice President of Drug Discovery | no data | no data | no data | |
| VP & Head of Toxicology | no data | no data | no data |
Experienced Management: BBOT's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.8yrs | US$20.00k | no data | |
| Co-Founder | 2.1yrs | US$700.35k | 0% $ 0 | |
| Chief Executive Officer and Director | less than a year | US$3.11m | 0.0036% $ 21.6k | |
| Independent Chairman of the Board | 1.2yrs | US$934.37k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$408.27k | 0% $ 0 | |
| Director | less than a year | US$20.00k | no data | |
| Member of Advisory Board | 1yr | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 2.2yrs | US$22.50k | no data | |
| Member of Advisory Board | 1yr | no data | no data | |
| Member of Advisory Board | 1yr | no data | no data |
Experienced Board: BBOT's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 06:58 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Oncology Therapeutics, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Robert Burns | H.C. Wainwright & Co. |